Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 7/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3705968 | 0.89 | SLC16A3 (0.39) | NFE2L2SLC16A3SLC16A1MET | |
| SCHEMBL3702686 | 0.89 | HTR6 (0.40) | NFE2L2 | |
| SCHEMBL4126123 | 0.89 | NAMPT (0.35) | SLC16A3SLC16A1NAMPT | |
| SCHEMBL476470 | 0.88 | HTR6 (0.36) | TAS2R14NAMPTSLC40A1 | |
| SCHEMBL18258907 | 0.88 | HTR6 (0.32) | NAMPT | |
| SCHEMBL3705969 | 0.88 | SLC16A3 (0.39) | NFE2L2SLC16A3SLC16A1METTAS2R14 | |
| SCHEMBL3703141 | 0.87 | CA1 (0.44) | NFE2L2SLC16A3SLC16A1METMTNR1B | |
| SCHEMBL476388 | 0.85 | PKM (0.38) | — | |
| SCHEMBL476365 | 0.85 | APLNR (0.35) | NAMPTGLO1SLC40A1 | |
| SCHEMBL4125767 | 0.84 | NFE2L2 (0.39) | NFE2L2SLC16A3SLC16A1METMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NFE2L2 2670/4885SLC16A3 2809/4885SLC16A1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.